Montana Molecular Awarded 350K SBIR Phase 1 from NIH to develop fluorescent assays for cell-based drug discovery.
BOZEMAN, MT. Montana Molecular was awarded an SBIR grant from the National Institute of Mental Health to develop fluorescent tools for detecting signaling events in living cells. These tools are designed to measure changes in second messengers- the molecules that relay signals within a cell- and will illuminate the cellular machinery that is switched on when receptors are activated either by a drug or during ordinary cellular function.
“There is a growing realization, in both drug discovery and basic research, of the need to make better measurements of specific second messenger components of cell signaling pathways and to monitor changes in real time and in relevant tissues and cells types. Our approach is leading to new discoveries that will enable new treatments for disease,” said Anne Marie Quinn, founder of Montana Molecular.
